TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02061800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
Study: NCT03665324

Intervention type: OTHER
Intervention: Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias
Description: Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study.
Study: NCT00474916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN5500
Description: Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KRN5500
Description: Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline given as dose escalation for placebo
Study: NCT02867696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based Intervention (TECH)
Description: Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month.
Study: NCT02588378

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging
Study: NCT02588378

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging
Study: NCT03789006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte Immunoglobulin (Rabbit)
Description: Induction agent for living donor kidney transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin 2 Receptor Antagonist
Description: Induction agent for living donor kidney transplantation
Study: NCT01045200

Intervention type: OTHER
Intervention: Comparison of follow-up
Description: Comparison of follow-up by nurse or surgeon after rectal cancer surgery
Study: NCT05462678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: Each patient performed two weekly sessions of 45 minutes each, for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Rehabilitation
Description: Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Rehabilitation
Description: Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
Study: NCT02588378

Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging
Study: NCT03903757

Intervention type: OTHER
Intervention: DNA methylome and total RNA sequencing
Description: Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features

Intervention type: OTHER
Intervention: DNA methylome and total RNA sequencing
Description: Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
Study: NCT00184587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02490657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (Saline 0.9%)
Study: NCT02627716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOS Plan
Description: It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~* Contact details / contact person~* Treatment and current follow-ups~* Medical care in the event of a crisis~* Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks.
Study: NCT02331576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT01355289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avatrombopag

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avatrombopag

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avatrombopag

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN)
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon (PEG-IFN)
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study: NCT03199105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education with image illustrations and/or local tetracaine mucilage
Description: The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education with image illustrations and/or local tetracaine mucilage
Description: The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
Study: NCT00997529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonmyeloablative stem cell transplant
Description: Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
Study: NCT02756442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory disorder assessment during sleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory disorder assessment during sleep
Study: NCT04581512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0042
Description: EP0042 Oral 20 mg 50 mg capsules
Study: NCT00283959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study: NCT02402036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib orally for 21 days every 28 day cycle
Study: NCT03381742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 75 mg once daily for 5 consecutive days at least.
Study: NCT04507373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin 40mg
Description: 40mg oral daily for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: 40mg oral daily for 10 weeks
Study: NCT04450810

Intervention type: OTHER
Intervention: Observation of serum and salivary NLRP3 levels
Description: Evaluation of serum and salivary NLRP3 levels

Intervention type: OTHER
Intervention: Observation of serum and salivary NLRP3 levels
Description: Evaluation of serum and salivary NLRP3 levels

Intervention type: OTHER
Intervention: Observation of serum and salivary NLRP3 levels
Description: Evaluation of serum and salivary NLRP3 levels

Intervention type: OTHER
Intervention: Observation of serum and salivary NLRP3 levels
Description: Evaluation of serum and salivary NLRP3 levels
Study: NCT04613778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture is a low-level laser technique with no invasive procedure
Study: NCT03923803

Intervention type: DIAGNOSTIC_TEST
Intervention: C- reactive protein
Description: the measurement will be done by chemileumeniscence

Intervention type: DIAGNOSTIC_TEST
Intervention: Pro calcitonin
Description: the measurement will be done by chemileumeniscence
Study: NCT02955251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-428
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-428
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-428
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-428
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
Study: NCT01097200

Intervention type: DEVICE
Group type: OTHER
Intervention: Elevate mesh
Description: The correction of the prolapse can be made by this new technique.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sacrocolpopexy
Description: Attach a mesh between the vagina and the promontorium.
Study: NCT01653379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001
Description: DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
Study: NCT04689412

Intervention type: DRUG
Intervention: Resveratrol
Description: Nasal administration of resveratrol
Study: NCT02427178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Allogeneic Stem Cells
Description: HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
Study: NCT00130312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: 100 mg gelcap in the morning and evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo gelcap in the morning and evening
Study: NCT03363022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
Study: NCT04779749

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT03821662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OT Diabetes Self-Management Intervention
Description: Occupational therapy chronic disease self-management intervention.
Study: NCT03386877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal regeneration
Description: Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal regeneration
Description: Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
Study: NCT03348592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (p-inulin)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
Study: NCT05512468

Intervention type: DRUG
Group type: OTHER
Intervention: carbon dye
Description: Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
Study: NCT00743236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold ischemia procedure
Description: Cold ischemia followed by partial nephrectomy
Study: NCT04235855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic USG guided Liver biopsy
Description: Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Liver Biopsy
Description: All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
Study: NCT02347787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPaCT
Description: The IMPaCT intervention has three stages:~1. Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~2. Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~3. Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Study: NCT04557644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-items-questionnaires addressing CI, disgust and empathy
Description: 7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saarbrucken Personality questionnaire (SPQ) addressing empathy.
Description: Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
Study: NCT01355289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study: NCT02676258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Si-Hy (olifilcon B)
Description: Wear Si-Hy silicone hydrgel soft contact lens for 3 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vistakon (narafilcon A)
Description: Wear Vistakon soft contact lens for 3 months